CTLA4 and posterior cortical atrophy: A phase II trial evaluating durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) with olaparib in HRR-deficient solid tumors demonstrated synergistic immunogenic cell death and disease stabilization, supporting further exploration in PCa cohorts (Fumet et al., 2020).